PHARMACORP RX INC (PCRX.CA) Fundamental Analysis & Valuation

TSX-V:PCRX • CA71714X1050

Current stock price

0.415 CAD
-0.01 (-1.19%)
Last:

This PCRX.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PCRX.CA Profitability Analysis

1.1 Basic Checks

  • In the past year PCRX has reported negative net income.
  • In the past year PCRX had a positive cash flow from operations.
PCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFPCRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -500K -1M -1.5M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 0.48%, PCRX is doing worse than 81.25% of the companies in the same industry.
  • With a Return On Equity value of 0.63%, PCRX is not doing good in the industry: 81.25% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROIC N/A
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCRX.CA Yearly ROA, ROE, ROICPCRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

  • PCRX's Profit Margin of 1.08% is on the low side compared to the rest of the industry. PCRX is outperformed by 75.00% of its industry peers.
  • Looking at the Gross Margin, with a value of 39.77%, PCRX belongs to the top of the industry, outperforming 87.50% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 1.08%
GM 39.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCRX.CA Yearly Profit, Operating, Gross MarginsPCRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 20 -20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PCRX.CA Health Analysis

2.1 Basic Checks

  • PCRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PCRX has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX.CA Yearly Shares OutstandingPCRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 20M 40M 60M 80M 100M
PCRX.CA Yearly Total Debt VS Total AssetsPCRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • An Altman-Z score of 4.94 indicates that PCRX is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 4.94, PCRX belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Debt to FCF ratio of PCRX is 2.81, which is a good value as it means it would take PCRX, 2.81 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of PCRX (2.81) is better than 100.00% of its industry peers.
  • PCRX has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
  • PCRX has a better Debt to Equity ratio (0.13) than 100.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Altman-Z 4.94
ROIC/WACCN/A
WACC8.05%
PCRX.CA Yearly LT Debt VS Equity VS FCFPCRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 10M 20M 30M

2.3 Liquidity

  • PCRX has a Current Ratio of 2.53. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • PCRX has a better Current ratio (2.53) than 100.00% of its industry peers.
  • A Quick Ratio of 1.79 indicates that PCRX should not have too much problems paying its short term obligations.
  • PCRX's Quick ratio of 1.79 is amongst the best of the industry. PCRX outperforms 100.00% of its industry peers.
Industry RankSector Rank
Current Ratio 2.53
Quick Ratio 1.79
PCRX.CA Yearly Current Assets VS Current LiabilitesPCRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. PCRX.CA Growth Analysis

3.1 Past

  • The earnings per share for PCRX have decreased by -5.98% in the last year.
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%

3.2 Future

  • Based on estimates for the next years, PCRX will show a very strong growth in Earnings Per Share. The EPS will grow by 64.40% on average per year.
  • PCRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 137.64% yearly.
EPS Next Y100%
EPS Next 2Y79.49%
EPS Next 3Y64.4%
EPS Next 5YN/A
Revenue Next Year257.94%
Revenue Next 2Y205.97%
Revenue Next 3Y137.64%
Revenue Next 5YN/A

3.3 Evolution

PCRX.CA Yearly Revenue VS EstimatesPCRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 20M 40M 60M
PCRX.CA Yearly EPS VS EstimatesPCRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2026 2027 0.01 0.02 0.03

More info and screens

Find the best growth stocksShow best growing peers

2

4. PCRX.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Forward Earnings ratio of 27.39, the valuation of PCRX can be described as expensive.
  • PCRX's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. PCRX is more expensive than 75.00% of the companies in the same industry.
  • PCRX's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 38.68.
Industry RankSector Rank
PE N/A
Fwd PE 27.39
PCRX.CA Price Earnings VS Forward Price EarningsPCRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued more expensive than 93.75% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PCRX is valued a bit more expensive than the industry average as 75.00% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 46.93
EV/EBITDA 130.81
PCRX.CA Per share dataPCRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.05 0.1 0.15

4.3 Compensation for Growth

  • PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as PCRX's earnings are expected to grow with 64.40% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y79.49%
EPS Next 3Y64.4%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCRX.CA Dividend Analysis

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCRX.CA Fundamentals: All Metrics, Ratios and Statistics

PHARMACORP RX INC

TSX-V:PCRX (4/20/2026, 7:00:00 PM)

0.415

-0.01 (-1.19%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-29
Earnings (Next)04-20
Inst Owners9.84%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap72.24M
Revenue(TTM)17.60M
Net Income(TTM)189.60K
Analysts80
Price Target0.59 (42.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.39
P/S 4.1
P/FCF 46.93
P/OCF 44.94
P/B 2.41
P/tB 9.03
EV/EBITDA 130.81
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY3.65%
FCF(TTM)0.01
FCFY2.13%
OCF(TTM)0.01
OCFY2.23%
SpS0.1
BVpS0.17
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA 0.48%
ROE 0.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 1.08%
GM 39.77%
FCFM 8.74%
ROA(3y)-14.02%
ROA(5y)N/A
ROE(3y)-14.35%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF 2.81
Debt/EBITDA 7
Cap/Depr 8.65%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion 293.95%
Profit Quality 811.87%
Current Ratio 2.53
Quick Ratio 1.79
Altman-Z 4.94
F-Score6
WACC8.05%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.14%
EPS Next Y100%
EPS Next 2Y79.49%
EPS Next 3Y64.4%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%334.83%
Revenue Next Year257.94%
Revenue Next 2Y205.97%
Revenue Next 3Y137.64%
Revenue Next 5YN/A
EBIT growth 1Y-174.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.45%
EBIT Next 3Y111.82%
EBIT Next 5YN/A
FCF growth 1Y122.73%
FCF growth 3Y518.15%
FCF growth 5YN/A
OCF growth 1Y124.06%
OCF growth 3Y529.96%
OCF growth 5YN/A

PHARMACORP RX INC / PCRX.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PHARMACORP RX INC (PCRX.CA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PCRX.CA.


Can you provide the valuation status for PHARMACORP RX INC?

ChartMill assigns a valuation rating of 2 / 10 to PHARMACORP RX INC (PCRX.CA). This can be considered as Overvalued.


Can you provide the profitability details for PHARMACORP RX INC?

PHARMACORP RX INC (PCRX.CA) has a profitability rating of 1 / 10.


What is the financial health of PHARMACORP RX INC (PCRX.CA) stock?

The financial health rating of PHARMACORP RX INC (PCRX.CA) is 7 / 10.